463 related articles for article (PubMed ID: 18952826)
1. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
Shibata-Koyama M; Iida S; Okazaki A; Mori K; Kitajima-Miyama K; Saitou S; Kakita S; Kanda Y; Shitara K; Kato K; Satoh M
Glycobiology; 2009 Feb; 19(2):126-34. PubMed ID: 18952826
[TBL] [Abstract][Full Text] [Related]
2. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides.
Shoji-Hosaka E; Kobayashi Y; Wakitani M; Uchida K; Niwa R; Nakamura K; Shitara K
J Biochem; 2006 Dec; 140(6):777-83. PubMed ID: 17038352
[TBL] [Abstract][Full Text] [Related]
4. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
Davies J; Jiang L; Pan LZ; LaBarre MJ; Anderson D; Reff M
Biotechnol Bioeng; 2001 Aug; 74(4):288-94. PubMed ID: 11410853
[TBL] [Abstract][Full Text] [Related]
5. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
6. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
[TBL] [Abstract][Full Text] [Related]
7. Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding.
Edberg JC; Kimberly RP
J Immunol; 1997 Oct; 159(8):3849-57. PubMed ID: 9378972
[TBL] [Abstract][Full Text] [Related]
8. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
Isoda Y; Yagi H; Satoh T; Shibata-Koyama M; Masuda K; Satoh M; Kato K; Iida S
PLoS One; 2015; 10(10):e0140120. PubMed ID: 26444434
[TBL] [Abstract][Full Text] [Related]
9. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
Ferrara C; Grau S; Jäger C; Sondermann P; Brünker P; Waldhauer I; Hennig M; Ruf A; Rufer AC; Stihle M; Umaña P; Benz J
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12669-74. PubMed ID: 21768335
[TBL] [Abstract][Full Text] [Related]
10. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1.
Matsumiya S; Yamaguchi Y; Saito J; Nagano M; Sasakawa H; Otaki S; Satoh M; Shitara K; Kato K
J Mol Biol; 2007 May; 368(3):767-79. PubMed ID: 17368483
[TBL] [Abstract][Full Text] [Related]
11. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
J Immunol Methods; 2005 Nov; 306(1-2):93-103. PubMed ID: 16236307
[TBL] [Abstract][Full Text] [Related]
12. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
Niwa R; Natsume A; Uehara A; Wakitani M; Iida S; Uchida K; Satoh M; Shitara K
J Immunol Methods; 2005 Nov; 306(1-2):151-60. PubMed ID: 16219319
[TBL] [Abstract][Full Text] [Related]
13. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa.
Okazaki A; Shoji-Hosaka E; Nakamura K; Wakitani M; Uchida K; Kakita S; Tsumoto K; Kumagai I; Shitara K
J Mol Biol; 2004 Mar; 336(5):1239-49. PubMed ID: 15037082
[TBL] [Abstract][Full Text] [Related]
14. Cell type-specific and site directed N-glycosylation pattern of FcγRIIIa.
Zeck A; Pohlentz G; Schlothauer T; Peter-Katalinić J; Regula JT
J Proteome Res; 2011 Jul; 10(7):3031-9. PubMed ID: 21561106
[TBL] [Abstract][Full Text] [Related]
15. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms.
Ferrara C; Stuart F; Sondermann P; Brünker P; Umaña P
J Biol Chem; 2006 Feb; 281(8):5032-6. PubMed ID: 16330541
[TBL] [Abstract][Full Text] [Related]
16. Quantitative in vivo comparisons of the Fc gamma receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody.
Scallon B; McCarthy S; Radewonuk J; Cai A; Naso M; Raju TS; Capocasale R
Int Immunopharmacol; 2007 Jun; 7(6):761-72. PubMed ID: 17466910
[TBL] [Abstract][Full Text] [Related]
17. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252
[TBL] [Abstract][Full Text] [Related]
18. A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa.
de Haas M; Koene HR; Kleijer M; de Vries E; Simsek S; van Tol MJ; Roos D; von dem Borne AE
J Immunol; 1996 Apr; 156(8):2948-55. PubMed ID: 8609432
[TBL] [Abstract][Full Text] [Related]
19. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
Ferrara C; Brünker P; Suter T; Moser S; Püntener U; Umaña P
Biotechnol Bioeng; 2006 Apr; 93(5):851-61. PubMed ID: 16435400
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.
Kanda Y; Imai-Nishiya H; Kuni-Kamochi R; Mori K; Inoue M; Kitajima-Miyama K; Okazaki A; Iida S; Shitara K; Satoh M
J Biotechnol; 2007 Jun; 130(3):300-10. PubMed ID: 17559959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]